<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under Section 12(g) of
the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under
Sections 13 and 15(d) of the Securities Exchange Act of 1934.
Commission File Number: 000-14680
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
ONE KENDALL SQUARE
CAMBRIDGE, MASSACHUSETTS 02139
(617) 252-7500
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
GENZYME SURGICAL PRODUCTS DIVISION COMMON STOCK, $0.01 PAR VALUE
GENZYME TISSUE REPAIR DIVISION COMMON STOCK, $0.01 PAR VALUE
GSP STOCK PURCHASE RIGHTS
GTR STOCK PURCHASE RIGHTS
(Title of each class of securities covered by this Form)
GENZYME GENERAL DIVISION COMMON STOCK, $0.01 PAR VALUE
GENZYME MOLECULAR ONCOLOGY DIVISION COMMON STOCK, $0.01 PAR VALUE
GENZYME BIOSURGERY DIVISION COMMON STOCK, $0.01 PAR VALUE
GGD STOCK PURCHASE RIGHTS
GMO STOCK PURCHASE RIGHTS
GBS STOCK PURCHASE RIGHTS
(Title of all other classes of securities for which a duty
to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12(g)-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ]
Rule 12(g)-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12(g)-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12(g)-4(a)(2)(ii) [ ] Rule 15d-6 [ ]
Rule 12h-3(b)(1)(i) [X]
Approximate number of holders of record as of the certification or notice date:
NONE.
Pursuant to the requirements of the Securities Exchange Act of 1934,
Genzyme Corporation has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
Date: DECEMBER 19, 2000 GENZYME CORPORATION
By: /s/ Michael S. Wyzga
-----------------------
Name: Michael S. Wyzga
Title: Senior Vice President and Chief
Financial Officer
